Medicine
Hysingla ER 20 mg extended-release tablet
Hysingla ER 20 mg extended-release tablet is a prescription medicine containing Hydrocodone for oral use, marketed by Knoa Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted between 15°-30°C (59°-86°F). Store…
Key facts
- Active ingredient (INN)
- Hydrocodone
- Brand
- Hysingla ER
- Strength
- 20 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 60 tablets
- Marketing authorisation holder
- Knoa Pharma
- Manufacturer
- Knoa Pharma
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted between 15°-30°C (59°-86°F). Store HYSINGLA ER securely and dispose of properly.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CII
- ATC code
- R05DA03 Hydrocodone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 January 2015
- Identifiers
- RxCUI 1595730, 1595736, 1595740 +7DailyMed set ID b7d23ac2-e776-9f62-3290-c64c2d6eb353NDC 59011-271Application NDA206627
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet, extended release in 1 bottle, plastic | 59011-271-60 | Knoa Pharma | 15 January 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 October 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Hydrocodone 20 mg extended-release tablet.
Other strengths and forms of Hydrocodone
Clinical summary
Hydrocodone is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids, among other approved uses. MedsAcross supplies Hydrocodone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about HydrocodoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Hysingla ER prescribing information (Knoa Pharma) · U.S. National Library of Medicine, DailyMed
Need Hysingla ER 20 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.